Park Square has placed David Moller, MD, as Chief Scientific Officer at Poxel SA.
| less than a minute read
Poxel Appoints Industry Leader Dr. David E. Moller as Chief Scientific Officer
Get in touch
Get in touch
POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced the appointment of David E. Moller, MD, as Chief Scientific Officer (CSO).
Get in touch
Get in touch
Latest Insights
/Passle/58a5cb8db00e8110e83aa395/MediaLibrary/Images/2026-09-01-21-26-53-841-6a97431d406533fea8d4615c.gif)
/Passle/58a5cb8db00e8110e83aa395/MediaLibrary/Images/2026-09-01-15-07-30-357-6a96ea32ce35c90f7ee74028.jpg)
/Passle/58a5cb8db00e8110e83aa395/MediaLibrary/Images/2026-08-24-14-26-15-201-6a8c5487b4553f6e28c0bcb7.jpg)
/Passle/58a5cb8db00e8110e83aa395/SearchServiceImages/2026-08-19-20-29-57-758-6a8612450e2b381c3863fcf2.jpg)